SeaStar Medical Holding 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- SeaStar Medical reported 3rd quarter 2026 net revenue of approximately $635,000, up 247% from approximately $183,000 in the 3rd quarter of 2025, reflecting increased Kuelimune demand.
- Gross profit percentage was over 90% in the 3rd quarter of 2026, consistent with prior quarters this year.
- Operating expenses were $5.2 million, compared with $3.7 million in the 3rd quarter of 2025; net loss was approximately $4.5 million, or $1.03 per share, compared with approximately $3.5 million, or $1.30 per share.
- Cash was approximately $4 million at September 30th, 2026, compared with approximately $12 million at December 31st, 2025; the September 30th balance excluded $3.3 million of gross proceeds from warrant exercises in October.
- Nine-month KuoLimune net revenue more than doubled to $1.7 million, and the company had 20 current customers among the top 50 pediatric medical centers it targets, with 10 new customers added so far in 2026.
- In the SAVE registry, no device-related adverse events were reported across 50 treated patients; 90-day survival was 65% for Qualimmune-treated patients versus 47% in the KID cohort, a statistically significant difference with a p-value of 0.043.
- The FDA granted breakthrough device designation for the SCD therapy for treatment of hyperinflammation in adult patients with sepsis or a septic condition, the therapy’s 7th indication to receive the designation.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for standing by, and welcome to SeaStar Medical Reports Third Quarter 2026 Financial Results Call. Currently, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. To remove yourself from the queue, you may press star one one again. I would now like to hand the call over to Jackie Cossmon. Please go ahead. Thank you, Lateef.
Good afternoon, and thank you for joining the SeaStar Medical Third Quarter 2026 Financial Results Conference Call. I'm Jackie Cossmon with Wheelhouse Life Science Advisors. Joining me from SeaStar Medical today are Eric Schlorff, Chief Executive Officer, Tim Varacek, Senior Vice President of Commercial and Business Operations, Dr. Kevin Chung, Chief Medical Officer, and Mike Messinger, Chief Financial Officer. I would like to remind listeners that comments made during this call by management will include forward-looking statements within the meaning of federal securities laws. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results. For a list and description of these risks and uncertainties, please review SeaStar Medical's filings with the Securities and Exchange Commission.
Furthermore, the content of this conference call contains information that is accurate only as of the date of the live broadcast, November 11, 2026. SeaStar Medical undertakes no obligation to revise or update any statements to reflect events or circumstances, except as required by law. Now, I'll turn the call over to Eric.
Eric? Thank you, Jackie, and thank you all for joining us today.
We made good progress on several fronts this quarter. We saw strong QUELIMMUNE demand in the ultra-rare pediatric AKI market, and we continue to build momentum in educating the critical care pediatric healthcare community. Kevin Chung, our CMO, presented data on QUELIMMUNE at several medical meetings, and we are already sharing with critical care professionals the statistically significant higher survival in QUELIMMUNE-treated patients in our patient registry that was highlighted at the late-breaking presentation at ASN Kidney Week 2026. Importantly, we believe this growing momentum of interest reinforces the promise of our SCD therapy for our pipeline indications, the first of which is for adult patients with AKI on continuous renal replacement therapy, or CRRT. The NEUTRALIZE-AKI pivotal clinical trial for this patient population is well underway and has enrolled about 75% of its intended 339 patients.
The results of this trial will be critical for understanding the role of our SCD therapy in preventing lifelong dialysis treatment and saving lives. As we have said previously, our enrollment in this trial is moderated by strict inclusion and exclusion criteria designed to enroll patients most appropriate for the study, which supports a well-defined trial population and more rigorous evaluation of the SCD's potential benefit in these patients. As a result, we are adjusting our guidance for completion of enrollment in the trial. Based on our current enrollment rate, we would anticipate completing the trial by mid-year of 2027. As we continue to add new sites and work with existing sites to ensure they are fully supported in recruiting and enrolling patients, this timeline could shorten, but we would like to be cautious in our prediction at this time.
We are clearly disappointed to extend the timeline for completion of enrollment, but our highest priority is that the study is conducted to provide our SCD therapy the opportunity for an optimized outcome and ultimately be available to patients. Now, turning to the pre-market approval, or PMA, application for adult AKI indication. We are working in parallel to accelerate the path to approval by preparing and submitting modules of the PMA to the FDA in advance of submitting the NEUTRALIZE-AKI clinical results. We have submitted the first module and are preparing additional modules for submission over the coming months. Also, our Breakthrough Device Designation for this indication should enable a priority review of the PMA once we submit the final module with the NEUTRALIZE-AKI clinical results, provided a positive outcome in the trial.
Another important event this quarter was the receipt of the Breakthrough Device Designation from the FDA for our SCD therapy for the treatment of hyperinflammation in adult patients with sepsis or a septic condition. I've asked Kevin to provide more detail on the importance of this indication, but I'd like to underscore the fact that this is a significant area of unmet need, and our existing NEUTRALIZE-AKI trial was designed to include a pre-specified analysis to capture the potential benefit of the SCD therapy in patients with sepsis. As such, when we complete the trial, we should have significant data to demonstrate the impact of the SCD therapy as a potential treatment for patients with AKI and sepsis.
Finally, before I turn the call over to Tim to discuss our plans for continued adoption of QUELIMMUNE, I'd like to recognize members of our military services who are being commemorated today, including Kevin, who has served his country as a military combat physician. In fact, Kevin was recently awarded the Combat Nephrology Award that he received at the Update in Critical Care Nephrology meeting in Madrid, Spain, where he was also the keynote speaker. The award was established to recognize clinicians, researchers, and military medical officers who have made transformative contributions to renal support in extreme high-acuity trauma and combat casualty environments. It was awarded by his peers in the field, and I know Kevin was very honored to receive this award.
His drive and passion for the care of patients is unparalleled, and through his work at SeaStar, it is clear that he is truly fighting to save each and every life. Congratulations, Kevin, on a well-deserved honor. With that, I'll turn the call over to Tim.
Thanks, Eric, and thanks everyone for joining us today. As Eric indicated, we saw strong QUELIMMUNE demand this quarter, and we continue to build momentum educating the pediatric critical care and nephrology community. Our primary goal is to continue to expand the market to ensure every pediatric AKI patient has the opportunity to receive the QUELIMMUNE therapy. Our net revenue for QUELIMMUNE sales jumped significantly to over $630,000 in the quarter, increasing 247% compared to last year's third quarter net revenue. Nine-month net revenue more than doubled to $1.7 million, putting us in a position to exceed our guidance of $2 million in QUELIMMUNE revenue for the year. We're very excited to see the growing enthusiasm for our QUELIMMUNE therapy in this ultra-rare condition and expect this to continue in 2027.
Additionally, several recent advances pave the way for a potential smoother path to customer adoption in the future. These include FDA's confirmation that we've met the requirements of the mandatory post-approval SAVE Registry, which previously added significant institutional time and effort to the QUELIMMUNE adoption process within pediatric hospital systems. As we recently reported, the assignment of ICD-10-PCS codes by CMS will enable hospitals the ability to track and bill for procedures that use the QUELIMMUNE therapy. With respect to our strategy for 2027 and beyond, given the ultra-rare nature of this condition, we will continue to focus on the top 50 pediatric medical centers as our primary target for QUELIMMUNE adoption. 20 of these top 50 medical institutions are current customers, and we expect to continue to increase utilization with existing customers.
We have added 10 new customers so far in 2026 and plan to continue our push to add new customers throughout this year and beyond. Based on observed and published outcomes data, we believe our continued focus on QUELIMMUNE education and expansion will potentially save lives in the pediatric patient population and also build the foundation for a potential launch in adult AKI, a much larger and underserved population of patients. Thank you for your attention, and with that, I'll turn the presentation over to our Chief Medical Officer, Kevin Chung.
Kevin? Thanks, Tim, and thank you to everyone for listening to our call.
Thank you, Eric, for the kind words. I have spent my entire career caring for the sickest patients in the hospital, first as an army critical care physician caring for critically ill combat wounded, and through the COVID pandemic and beyond. One concept has struck with me. Patients with multiple organ failure and their families deserve better options. Current standards of care are not good enough. Before I turn to NEUTRALIZE-AKI, I would like to discuss the SAVE registry results that we presented at the ASN Kidney Week 2026 in late October. The selection of this data as a late breaker reflects the urgent need for better options for children with sepsis-associated AKI. It is difficult to describe how sick these children are.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
